BBIO NASDAQ
BridgeBio Pharma, Inc.
1W: +2.7%
1M: +4.1%
3M: -17.0%
YTD: -11.3%
1Y: +27.9%
3Y: +182.3%
5Y: +47.1%
$69.37
+1.22 (+1.79%)
Weekly Expected Move ±3.8%
$63
$66
$69
$71
$74
Credit Risk of going bust: lower than 52% of companies Debt: 15.5% of company value Bonds: $309.3M held by 77 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.42 (down 98%), BridgeBio Pharma, Inc. would be worth roughly what it owes.
Total debt $2.49B against a stock market value of $13.56B.
Distance to default 5.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.51B (short-term plus half of long-term), stock volatility 46.4%; Altman Z'' -14.10. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.42 (down 98%), BridgeBio Pharma, Inc. would be worth roughly what it owes.
Total debt $2.49B against a stock market value of $13.56B.
Distance to default 5.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.51B (short-term plus half of long-term), stock volatility 46.4%; Altman Z'' -14.10. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
FDA unveils rare disease initiative to enhance therapy development
BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
BridgeBio nabs Priority Review for infigratinib for achondroplasia
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
Top Analyst Reports for ExxonMobil, Automatic Data Processing & Cadence
BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study
BioMarin Stops Voxzogo Development for Noonan Syndrome
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $715,000 in BridgeBio Pharma, Inc. $BBIO
BridgeBio Pharma, Inc. $BBIO Shares Purchased by California State Teachers Retirement System
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
Frazier Life Sciences Management L.P. Sells 1,900,000 Shares of BridgeBio Pharma, Inc. $BBIO
HC Wainwright Forecasts Weaker Earnings for BridgeBio Pharma
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
AM Markets Need to Know: Nasdaq rebounds in August, Anthropic expands AI capacity, and more
Trump unveils new drug-pricing accords with CSL, Astellas, and other biotech drugmakers
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
White House is said to announce drug pricing deals with biotechs
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
BridgeBio (BBIO) Q2 2026 Earnings Call Transcript
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
BridgeBio outlines three launches with first PDUFA set for November 27, 2026 and RECLAIM-HP readout in next 18 months
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates
Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
California State Teachers Retirement System Boosts Stock Position in BridgeBio Pharma, Inc. $BBIO
1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree.
Alnylam drops after guidance cut on ATTR-CM headwinds
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?
Affinity Asset Advisors LLC Has $11.14 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO
California Public Employees Retirement System Grows Stock Holdings in BridgeBio Pharma, Inc. $BBIO
Atika Capital Management LLC Acquires Shares of 35,200 BridgeBio Pharma, Inc. $BBIO
FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug
Allspring Global Investments Holdings LLC Sells 104,864 Shares of BridgeBio Pharma, Inc. $BBIO
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
BridgeBio gains as muscular dystrophy therapy gets FDA priority review
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO)
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
BridgeBio outlines $500M share repurchase as it targets P&L breakeven in 2027
BridgeBio (BBIO) Q1 2026 Earnings Transcript
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
BridgeBio Pharma GAAP EPS of -$0.84 misses by $0.16, revenue of $194.5M beats by $15.89M
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
Here are the major earnings after the close Thursday
BridgeBio to Participate in May and June Investor Conferences
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
Gartner Gears Up to Report Q1 Earnings: What's in the Offing?
IQVIA Set to Report Q1 Earnings: Here's What You Should Know
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
BridgeBio (BBIO) Q2 2025 Earnings Transcript
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
BridgeBio gains after settlement in Pfizer Vyndamax patent dispute
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
B. Metzler seel. Sohn & Co. AG Cuts Position in BridgeBio Pharma, Inc. $BBIO
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Rep. Gilbert Ray Cisneros, Jr. Buys BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares
ClearBridge SMID Cap Growth strategy initiates new positions, exits several in Q1
Allspring Global Investments Holdings LLC Has $77.78 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
Central Pacific Bank Trust Division Makes New $789,000 Investment in BridgeBio Pharma, Inc. $BBIO
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
Neil Kumar Sells 40,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock
Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress
Equities Analysts Set Expectations for BBIO Q1 Earnings
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
Victory Capital Management Inc. Purchases 141,800 Shares of BridgeBio Pharma, Inc. $BBIO